The role of antibodies in multiple sclerosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 2, 2011, Pages 239-245

  Weber, Martin S ^a   Hemmer Bernhard, B ^a   Cepok, Sabine ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody; B cell; Experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

AUTOANTIBODY; CD20 ANTIBODY; CORTICOTROPIN; CYCLOPHOSPHAMIDE; RITUXIMAB;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; B LYMPHOCYTE; DISEASE ASSOCIATION; EFFECTOR CELL; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; AUTOANTIBODIES; B-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; LYMPHOCYTE DEPLETION; MICE; MULTIPLE SCLEROSIS; PLASMA EXCHANGE;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 78650172728     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.06.009     Document Type: Review

References (105)

1. Kabat E.A., Moore D.H., Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their reletionship to the serum proteins. J. Clin. Invest. 1942, 21:571-577.
2. Owens G.P., Kraus H., Burgoon M.P., Smith-Jensen T., Devlin M.E., Gilden D.H. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann. Neurol. 1998, 43:236-243.
3. Baranzini S.E., Jeong M.C., Butunoi C., Murray R.S., Bernard C.C., Oksenberg J.R. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 1999, 163:5133-5144.
4. Owens G.P., Burgoon M.P., Anthony J., Kleinschmidt-DeMasters B.K., Gilden D.H. The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes. Clin. Immunol. 2001, 98:258-263.
5. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
6. Lassmann H., Bruck W., Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 2001, 7:115-121.
7. Breij E.C., Brink B.P., Veerhuis R., van den B.C., Vloet R., Yan R., Dijkstra C.D., Bo L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63:16-25.
8. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998, 43:465-471.
9. Cepok S., von Geldern G., Grummel V., Hochgesand S., Celik H., Hartung H., Hemmer B. Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J. Neuroimmunol. 2006, 180:33-39.
10. Cepok S., Jacobsen M., Schock S., Omer B., Jaekel S., Boddeker I., Oertel W.H., Sommer N., Hemmer B. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001, 124:2169-2176.
11. Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J., Sommer N., Hartung H.P., Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005, 128:1667-1676.
12. Cepok S., Zhou D., Vogel F., Rosche B., Grummel V., Sommer N., Hemmer B. The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch. Neurol. 2003, 60:849-855.
13. Cepok S., von G.G., Nolting T., Grummel V., Srivastava R., Zhou D., Hartung H.P., Adams O., Arendt G., Hemmer B. Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann. Neurol. 2007, 62(5):458-467.
14. Qin Y., Duquette P., Zhang Y., Talbot P., Poole R., Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 1998, 102:1045-1050.
15. Qin Y., Duquette P., Zhang Y., Olek M., Da R.R., Richardson J., Antel J.P., Talbot P., Cashman N.R., Tourtellotte W.W., Wekerle H., Van Den N.S. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab. Invest. 2003, 83:1081-1088.
16. Colombo M., Dono M., Gazzola P., Roncella S., Valetto A., Chiorazzi N., Mancardi G.L., Ferrarini M. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 2000, 164:2782-2789.
17. Owens G.P., Ritchie A.M., Burgoon M.P., Williamson R.A., Corboy J.R., Gilden D.H. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. 2003, 171:2725-2733.
18. Owens G.P., Winges K.M., Ritchie A.M., Edwards S., Burgoon M.P., Lehnhoff L., Nielsen K., Corboy J., Gilden D.H., Bennett J.L. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J. Immunol. 2007, 179:6343-6351.
19. Winges K.M., Gilden D.H., Bennett J.L., Yu X., Ritchie A.M., Owens G.P. Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J. Neuroimmunol. 2007, 192:226-234.
20. Obermeier B., Mentele R., Malotka J., Kellermann J., Kumpfel T., Wekerle H., Lottspeich F., Hohlfeld R., Dornmair K. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 2008, 14:688-693.
21. von Budingen H.C., Harrer M.D., Kuenzle S., Meier M., Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur. J. Immunol. 2008, 38:2014-2023.
22. Walsh M.J., Tourtellotte W.W. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J. Exp. Med. 1986, 163:41-53.
23. Colombo M., Dono M., Gazzola P., Chiorazzi N., Mancardi G., Ferrarini M. Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients. Eur. J. Immunol. 2003, 33:3433-3438.
24. Farrell M.A., Kaufmann J.C., Gilbert J.J., Noseworthy J.H., Armstrong H.A., Ebers G.C. Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation. Neurology 1985, 35:212-218.
25. Izquierdo G., Angulo S., Garcia-Moreno J.M., Gamero M.A., Navarro G., Gata J.M., Ruiz-Pena J.L., Paramo M.D. Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol. Scand. 2002, 105:158-163.
26. Avasarala J.R., Cross A.H., Trotter J.L. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch. Neurol. 2001, 58:2044-2045.
27. Koch M., Heersema D., Mostert J., Teelken A., De K.J. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis. Eur. J. Neurol. 2007, 14:797-800.
28. Villar L.M., Masjuan J., Gonzalez-Porque P., Plaza J., Sadaba M.C., Roldan E., Bootello A., Alvarez-Cermeno J.C. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002, 59:555-559.
29. Villar L.M., Masjuan J., Gonzalez-Porque P., Plaza J., Sadaba M.C., Roldan E., Bootello A., Alvarez-Cermeno J.C. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 2003, 53:222-226.
30. Schneider R., Euler B., Rauer S. Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur. J. Neurol. 2007, 14:907-911.
31. Vandvik B., Norrby E., Nordal H.J., Degre M. Oligoclonal measles virus-specific IgG antibodies isolated from cerebrospinal fluids, brain extracts, and sera from patients with subacute sclerosing panencephalitis and multiple sclerosis. Scand. J. Immunol. 1976, 5:979-992.
32. Sauerbrei A., Eichhorn U., Hottenrott G., Wutzler P. Virological diagnosis of herpes simplex encephalitis. J. Clin. Virol. 2000, 17:31-36.
33. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5:170-175.
34. O'Connor K.C., Appel H., Bregoli L., Call M.E., Catz I., Chan J.A., Moore N.H., Warren K.G., Wong S.J., Hafler D.A., Wucherpfennig K.W. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J. Immunol. 2005, 175:1974-1982.
35. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., Poewe W., Berger T. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999, 122:2047-2056.
36. Schmidt S., Haase C.G., Bezman L., Moser H., Schmidt M., Kohler W., Linington C., Klockgether T. Serum autoantibody responses to myelin oligodendrocyte glycoprotein and myelin basic protein in X-linked adrenoleukodystrophy and multiple sclerosis. J. Neuroimmunol. 2001, 119:88-94.
37. Antel J.P., Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis?. N Engl J. Med. 2003, 349:107-109.
38. Brilot F., Dale R.C., Selter R.C., et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann. Neurol. 2009, 66:833-842.
39. R.C. Selter, F. Brilot, V. Grummel, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology;74:1711-1715.
40. Archelos J.J., Storch M.K., Hartung H.P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 2000, 47:694-706.
41. Karni A., Bakimer-Kleiner R., Abramsky O., Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch. Neurol. 1999, 56:311-315.
42. Lampasona V., Franciotta D., Furlan R., Zanaboni S., Fazio R., Bonifacio E., Comi G., Martino G. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004, 62:2092-2094.
43. Rauer S., Euler B., Reindl M., Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J. Neurol. Neurosurg. Psychiatry 2006, 77:739-742.
44. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J. Med. 2003, 349:139-145.
45. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J. Med. 2007, 356:371-378.
46. Zhou D., Srivastava R., Nessler S., Grummel V., Sommer N., Bruck W., Hartung H.P., Stadelmann C., Hemmer B. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl Acad. Sci. USA 2006, 103:19057-19062.
47. Lalive P.H., Menge T., Delarasse C., Della G.B., Pham-Dinh D., Villoslada P., von Budingen H.C., Genain C.P. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc. Natl Acad. Sci. USA 2006, 103:2280-2285.
48. O'Connor K.C., McLaughlin K.A., De Jager P.L., Chitnis T., Bettelli E., Xu C., Robinson W.H., Cherry S.V., Bar-Or A., Banwell B., Fukaura H., Fukazawa T., Tenembaum S., Wong S.J., Tavakoli N.P., Idrissova Z., Viglietta V., Rostasy K., Pohl D., Dale R.C., Freedman M., Steinman L., Buckle G.J., Kuchroo V.K., Hafler D.A., Wucherpfennig K.W. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 2007, 13:211-217.
49. McLaughlin K.A., Chitnis T., Newcombe J., Franz B., Kennedy J., McArdel S., Kuhle J., Kappos L., Rostasy K., Pohl D., Gagne D., Ness J.M., Tenembaum S., O'Connor K.C., Viglietta V., Wong S.J., Tavakoli N.P., de Seze J., Idrissova Z., Khoury S.J., Bar-Or A., Hafler D.A., Banwell B., Wucherpfennig K.W. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J. Immunol. 2009, 183:4067-4076.
50. Vogt M.H., Teunissen C.E., Iacobaeus E., Heijnen D.A., Breij E.C., Olsson T., Brundin L., Killestein J., Dijkstra C.D. Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80:1110-1115.
51. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J. Med. 2000, 343:938-952.
52. Rio J., Comabella M., Montalban X. Predicting responders to therapies for multiple sclerosis. Nat. Rev. Neurol. 2009, 5:553-560.
53. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
54. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
55. Paul F., Jarius S., Aktas O., Bluthner M., Bauer O., Appelhans H., Franciotta D., Bergamaschi R., Littleton E., Palace J., Seelig H.P., Hohlfeld R., Vincent A., Zipp F. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007, 4:e133.
56. Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., DuPree C., Glogowska M., Case D., Antel J.P., Owens G.P., Gilden D., Nessler S., Stadelmann C., Hemmer B. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66:617-629.
57. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., Adzemovic M., Bauer J., Berger T., Fujihara K., Itoyama Y., Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
58. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., Lang W., Reindl M., Vincent A., Kristoferitsch W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131:3072-3080.
59. Gilden D.H. Infectious causes of multiple sclerosis. Lancet Neurol. 2005, 4:195-202.
60. Stohlman S.A., Hinton D.R. Viral induced demyelination. Brain Pathol. 2001, 11:92-106.
61. Martin R., Martens U., Sticht-Groh V., Dorries R., Kruger H. Persistent intrathecal secretion of oligoclonal, Borrelia burgdorferi-specific IgG in chronic meningoradiculomyelitis. J. Neurol. 1988, 235:229-233.
62. Owens G.P., Burgoon M.P., Devlin M.E., Gilden D.H. Strategies to identify sequences or antigens unique to multiple sclerosis. Mult. Scler. 1996, 2:184-194.
63. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science 1990, 249:386-390.
64. Cortese I., Tafi R., Grimaldi L.M., Martino G., Nicosia A., Cortese R. Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. Proc. Natl. Acad. Sci. U. S. A 1996, 93:11063-11067.
65. Rand K.H., Houck H., Denslow N.D., Heilman K.M. Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1998, 65:48-55.
66. Cortese I., Capone S., Luchetti S., Grimaldi L.M., Nicosia A., Cortese R. CSF-enriched antibodies do not share specificities among MS patients. Mult. Scler. 1998, 4:118-123.
67. Somers V., Govarts C., Somers K., Hupperts R., Medaer R., Stinissen P. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J. Immunol. 2008, 180:3957-3963.
68. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Bussow K., Sommer N., Hemmer B. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 2005, 115:1352-1360.
69. Owens G.P., Bennett J.L., Lassmann H., O'Connor K.C., Ritchie A.M., Shearer A., Lam C., Yu X., Birlea M., DuPree C., Williamson R.A., Hafler D.A., Burgoon M.P., Gilden D. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 2009, 65:639-649.
70. Yu X., Owens G.P., Gilden D.H. Rapid and efficient identification of epitopes/mimotopes from random peptide libraries. J. Immunol. Methods 2006, 316:67-74. %20.
71. Zhang Y., Da R.R., Guo W., Ren H.M., Hilgenberg L.G., Sobel R.A., Tourtellotte W.W., Smith M.A., Olek M., Gupta S., Robertson R.T., Nagra R., Van Den N.S., Qin Y. Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis. J. Clin. Immunol. 2005, 25:254-264.
72. Storch M., Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr. Opin. Neurol. 1997, 10:186-192.
73. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 1993, 143:555-564.
74. Marta C.B., Oliver A.R., Sweet R.A., Pfeiffer S.E., Ruddle N.H. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc. Natl Acad. Sci. USA 2005, 102:13992-13997.
75. Marta C.B., Montano M.B., Taylor C.M., Taylor A.L., Bansal R., Pfeiffer S.E. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J. Biol. Chem. 2005, 280:8985-8993.
76. Whitney K.D., McNamara J.O. Autoimmunity and neurological disease: antibody modulation of synaptic transmission. Annu. Rev. Neurosci. 1999, 22(75-95):175-195.
77. Berger T., Reindl M. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis. J. Neural Transm. Suppl. 2000, 351-360.
78. Ruprecht K., Klinker E., Dintelmann T., Rieckmann P., Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004, 63:1081-1083.
79. Weinshenker B.G., O'Brien P.C., Petterson T.M., Noseworthy J.H., Lucchinetti C.F., Dodick D.W., Pineda A.A., Stevens L.N., Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 1999, 46:878-886.
80. Keegan M., Konig F., McClelland R., Bruck W., Morales Y., Bitsch A., Panitch H., Lassmann H., Weinshenker B., Rodriguez M., Parisi J., Lucchinetti C.F. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005, 366:579-582.
81. Zettl U.K., Hartung H.P., Pahnke A., Brueck W., Benecke R., Pahnke J. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 2006, 67:1515-1516.
82. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
83. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J. Med. 2008, 358:676-688.
84. Bar-Or A., Fawaz L., Fan B., et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann. Neurol. 2010, 67(4):452-461.
85. M.S. Weber, T. PJC Prod́homme, T. Karnezis, N. Molnarfi, T. Karnezis, K. Lehmann-Horn, D.M. Danilenko, J. Eastham-Anderson, A. Slavin, C. Linington, C.C.A. Bernard, F. Martin, S.S. Zamvil. B cell activation influences T cell polarization and outcome of anti-CD20 B cell depletion in CNS autoimmunity. Ann Neurol; accepted for publication.
86. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990, 8:579-621.
87. Zamvil S., Nelson P., Trotter J., Mitchell D., Knobler R., Fritz R., Steinman L. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985, 317:355-358.
88. Lyons J.A., San M., Happ M.P., Cross A.H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. J. Immunol. 1999, 29:3432-3439.
89. Merkler D., Schmelting B., Czeh B., Fuchs E., Stadelmann C., Bruck W. Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult. Scler. 2006, 12:369-374.
90. Prineas J.W., Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978, 28:68-75.
91. Schluesener H.J., Sobel R.A., Linington C., Weiner H.L. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J. Immunol. 1987, 139:4016-4021.
92. Lyons J.A., Ramsbottom M.J., Cross A.H. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 2002, 32:1905-1913.
93. + T cells to protein antigens in vivo. J. Immunol. 1995, 155:3734-3741.
94. + T cells. J. Immunol. 1995, 154:4915-4923.
95. Oliver A.R., Lyon G.M., Ruddle N.H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 2003, 171:462-468.
96. von Budingen H.C., Hauser S.L., Fuhrmann A., Nabavi C.B., Lee J.I., Genain C.P. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc. Natl Acad. Sci. U. S. A. 2002, 99:8207-8212.
97. Bourquin C., Schubart A., Tobollik S., Mather I., Ogg S., Liblau R., Linington C. Selective unresponsiveness to conformational B cell epitopes of the myelin oligodendrocyte glycoprotein in H-2b mice. J. Immunol. 2003, 171:455-461.
98. von Budingen H.C., Hauser S.L., Ouallet J.C., Tanuma N., Menge T., Genain C.P. Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur. J. Immunol. 2004, 34:2072-2083.
99. Litzenburger T., Fassler R., Bauer J., Lassmann H., Linington C., Wekerle H., Iglesias A. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J. Exp. Med. 1998, 188:169-180.
100. Krishnamoorthy G., Lassmann H., Wekerle H., Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 2006, 116:2385-2392.
101. Bettelli E., Pagany M., Weiner H.L., Linington C., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 2003, 197:1073-1081.
102. Bettelli E., Baeten D., Jager A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 2006, 116:2393-2402.
103. Mandler R.N., Davis L.E., Jeffery D.R., Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann. Neurol. 1993, 34:162-168.
104. Cree B.A., Goodin D.S., Hauser S.L. Neuromyelitis optica. Semin. Neurol. 2002, 22:105-122.
105. Pollinger B., Krishnamoorthy G., Berer K., Lassmann H., Bosl M.R., Dunn R., Domingues H.S., Holz A., Kurschus F.C., Wekerle H. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 2009, 206:1303-1316.